Key result
Late chemotherapy toxicities in pediatric osteosarcoma patients include life-threatening secondary malignancies and anthracycline cardiomyopathies, as well as disabling hearing loss and renal issues.
Why the study?
With increasing long-term disease-free survival rates in osteosarcoma, long-term toxicities of successful therapy have gained increasing importance.
This review highlights the importance of managing late chemotherapy toxicities, including anthracycline cardiomyopathy, in pediatric osteosarcoma survivors.
With ever increasing long-term, disease free survival rates, long-term toxicities of otherwise successful therapy have gained increasing importance. They can be grouped into potentially life-threatening, especially secondary malignancies and anthracycline cardiomyopathies, potentially disabling, particularly severe hearing loss and renal insufficiency, other, and rare events. Pathophysiology, frequency, and medical treatment approaches are discussed. Finally, fertility issues and quality of life issues are discussed, together with an outlook into the future. The challenge to cure as many patients as possible from osteosarcoma while enabling a life free of late effects will remain.
No takes yet. Share an insight, caveat, or question.
Hecker‐Nolting et al. (2021) conducted a review in Pediatric osteosarcoma. Chemotherapy was evaluated. Late chemotherapy toxicities in pediatric osteosarcoma patients include life-threatening secondary malignancies and anthracycline cardiomyopathies, as well as disabling hearing loss and renal issues.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: